Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism
Open Access
- 15 May 2018
- journal article
- research article
- Published by Springer Nature in BMC Nephrology
- Vol. 19 (1) , 1-12
Abstract
The calcimimetic agent cinacalcet is effective for the management of secondary hyperparathyroidism (SHPT) in dialysis patients. Changes to reimbursement of cinacalcet in Australia provided an opportunity to assess effects of medication cessation on biochemical and clinical outcomes in dialysis patients, including changes to novel biomarkers such as calciprotein particles (CPP). CPP are nanoparticles of mineral and protein in the circulation associated with increased vascular calcification in patients with chronic kidney disease. Dialysis patients from a single center who ceased cinacalcet between August 2015 and March 2016 were included in a prospective observational study. Bloods were taken at the time of cessation of cinacalcet and at 1, 6 and 12 months. Clinical and biochemical outcomes were compared with an age- and gender-matched cohort of cinacalcet-naïve dialysis patients. Sixty-two patients participated in the study. Mean age was 69.6 ± 13.2 years. Biochemical changes over 12 months following cessation of cinacalcet included an increase in serum parathyroid hormone (PTH) (42.2 [IQR 27.8–94.6] pmol/L to 114.8 [83.9–159.1] pmol/L [p < 0.001]), serum calcium (2.31 ± 0.21 mmol/L to 2.46 ± 0.14 mmol/L [p < 0.001]) and primary CPP (CPP-I) (p = 0.002). Changes in CPP were associated with an increase in PTH (p = 0.007), calcium (p = 0.002) and ferritin (p = 0.02) but a reduction in serum albumin (p = 0.001). Over the 12-month period, there were two fractures, five cardiovascular events, one episode of calciphylaxis, and one parathyroidectomy, with a mortality rate of 19% (n = 13). Uniquely we report the effects of cinacalcet withdrawal in a real world setting with demonstrated increases in PTH, serum calcium and CPP subsets, novel CKD-MBD related factors, over a 12-month period.Keywords
Funding Information
- Amgen Australia- unrestricted investigator initiated research grant
This publication has 29 references indexed in Scilit:
- Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional linksClinical Interventions in Aging, 2013
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing DialysisNew England Journal of Medicine, 2012
- Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT studyNephrology Dialysis Transplantation, 2012
- Fetuin-Mineral Complex Reflects Extraosseous Calcification Stress in CKDJournal of the American Society of Nephrology, 2010
- PROGRESS IN UREMIC TOXIN RESEARCH: Parathyroid Hormone, A Uremic ToxinSeminars in Dialysis, 2009
- Fully phosphorylated fetuin-A forms a mineral complex in the serum of rats with adenine-induced renal failureKidney International, 2009
- Pathophysiology of Vascular Calcification in Chronic Kidney DiseaseCirculation Research, 2004
- THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Calcium Phosphate Metabolism and Cardiovascular Disease in Patients with Chronic Kidney DiseaseSeminars in Dialysis, 2003
- Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failureKidney International, 1990
- Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patientsKidney International, 1987